source
- Acadia’s Alzheimer’s psychosis drug misses primary goal but advances on secondary dataAcadia Pharmaceuticals reported that its investigational drug remlifanserin failed to meet the primary endpoint in the Phase 2 portion of the RADIANT trial for Alzheimer’s disease psychosis. The t…
- Merck’s eye-drug matches Lucentis in vision improvement but raises safety concernsMerck reported results from its Phase 2b/3 BRUNELLO trial of remigromig, a Wnt-pathway agonist for diabetic macular edema. The drug achieved non-inferior improvement in best-corrected visual acuit…